Should You Buy Synergy CHC Corp. Stock in 2026?
According to the CirclFi Deep Alpha Valuation Engine, Synergy CHC Corp. (SNYR) scores 4.6/10 on our Quality of Company framework, indicating mixed operational fundamentals. At the current price of $0.08, our multi-model valuation analyzes whether the market has already discounted these weaknesses.
The short answer: 1 of 1 CirclFi valuation models project upside for Synergy CHC Corp. (SNYR) at $0.08 — the model consensus leans bullish, with a Quality Score of 4.6/10 and Value-Trap risk of 53/100. The full bull case, bear case, and risk factors are below. Educational analysis, not financial advice.
What Is the Investment Case for Synergy CHC Corp. (SNYR) in 2026?
What Is the Bull Case vs the Bear Case for Synergy CHC Corp. (SNYR)?
| Bull case — $0.09 target (+13.8%) | Bear case |
|---|---|
| According to the CirclFi Deep Alpha Valuation Engine, the gap between the market price of $0.08 and the median fair value of $0.09 implies +13.8% upside potential. | No active model flags significant downside for SNYR. The Value Trap score of 53/100 still argues for some caution. |
How Does SNYR Compare to Its Medical Distribution Peers?
Valuation data pages: VNOV · COSM · ACH · MEDS · FOCL · HKPD · COR · YI · MCK
Which Other Stocks Score Like SNYR on Quality?
Closest companies to SNYR’s Quality of Company score of 4.6/10, across all industries.
- PTIX — Protagenic Therapeutics, Inc. (QOC 4.6) · analysis
- FLYE — Fly-E Group, Inc. (QOC 4.6) · analysis
- RBOT — Vicarious Surgical Inc. (QOC 4.6) · analysis
- OFS — OFS Capital Corporation (QOC 4.6) · analysis
- IRON — Disc Medicine, Inc. (QOC 4.6) · analysis
- BDRX — Biodexa Pharmaceuticals Plc (QOC 4.6) · analysis
- NVDA — NVIDIA Corporation (QOC 10.0) · analysis
So Is Synergy CHC Corp. (SNYR) Worth Buying in 2026?
The convergence of 4.6/10 quality, multi-model undervaluation (1/1 bullish, +13.8% median upside), and a median fair value of $0.09 vs. $0.08 current price makes Synergy CHC Corp. one of the more compelling opportunities in our coverage. As always, our models provide a quantitative starting point — not a substitute for individual due diligence.
These are quantitative model outputs, not investment recommendations. Synergy CHC Corp.'s future depends on factors — management execution, competitive dynamics, regulatory changes — that no algorithm can fully capture. See all 13 model estimates →
What Else Do Investors Ask About SNYR Stock?
Should I buy SNYR stock right now?
Based on CirclFi's multi-model analysis, 1 of 1 models see upside for SNYR at $0.08. The majority of models suggest the stock trades below fair value, but investors should weigh this against the Quality Score of 4.6/10 and individual risk tolerance. This is not a buy recommendation — see our full disclaimer.
What are the biggest risks of investing in Synergy CHC Corp.?
Key risks include: an elevated Value Trap score of 53/100, suggesting apparent undervaluation may mask deteriorating fundamentals; a below-average Quality Score of 4.6/10, indicating fundamental weakness; limited model coverage (1/13 active), reducing analytical confidence; general market and sector-specific risks affecting Medical Distribution companies. Always diversify and consult a financial advisor.
How does SNYR compare to its competitors?
Among Medical Distribution peers, SNYR holds a Quality Score of 4.6/10. Comparable companies include VNOV (QOC 5.6), COSM (QOC 4.5), ACH (QOC 5.7). The relative ranking helps investors identify whether SNYR offers better fundamental quality than alternatives in the same sector.
Is SNYR a good long-term investment?
Long-term investment potential depends on fundamental quality and sustainable competitive advantages. SNYR's Quality Score of 4.6/10 raises concerns about long-term viability without significant operational improvements. Check our full data page for all 13 model estimates.
What price should I buy SNYR at?
CirclFi does not provide target buy prices or price alerts. However, our 1 active models produce fair value estimates ranging from $0.09 to $0.09. At $0.08, the stock trades below even the most conservative estimate, which may represent a margin of safety — or reflect risks the models don't capture. Many value investors look for a 20-30% margin of safety below intrinsic value before buying.
Want the complete picture?
See all 13 model estimates, confidence scores, and the full valuation table for SNYR.
Disclaimer: This article is produced by the CirclFi Valuation Engine using quantitative models and is for educational and informational purposes only. It is not financial advice, a buy/sell recommendation, or a solicitation to trade securities. Past performance is not indicative of future results. All data sourced from SEC EDGAR, FRED, and GDELT. Consult a licensed financial advisor before making investment decisions. Full disclaimer →
Buy with Gumroad